![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intercept Pharmaceuticals Inc | NASDAQ:ICPT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 19.00 | 18.66 | 19.02 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on September 29, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Intercept Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 22-3868459 |
(State or other jurisdiction of | (I.R.S. Employer Identification No.) |
incorporation or organization) |
10 Hudson Yards, 37th Floor, New York, NY | 10001 |
(Address of Principal Executive Offices) | (Zip Code) |
Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan
(Full title of the plan)
Mary J. Grendell
Deputy General Counsel and Corporate Secretary
Intercept Pharmaceuticals, Inc.
10 Hudson Yards, 37th Floor
New York, NY 10001
(646) 747-1000 |
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
with copies to:
Graham Robinson and Timothy F. Nelson
Skadden, Arps, Slate, Meagher & Flom LLP
500 Boylston Street
Boston, MA 02116
(617) 573-4800
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x | Accelerated filer ¨ |
Non-accelerated filer ¨ | Smaller reporting company ¨ |
Emerging growth company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
Title of
securities to be registered |
Amount to be
registered(1) |
Proposed
maximum offering price per share |
Proposed
maximum aggregate offering price |
Amount of
registration fee |
Common Stock, par value $0.001 per share (“Common Stock”), reserved for future grant under the Registrant’s 2012 Equity Incentive Plan | 1,473,063(2) | $16.00225(3) | $23,572,322.39(3) | $2,571.74 |
(1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the Registrant’s 2012 Equity Incentive Plan (the “Plan”) by reason of any stock split, stock dividend, combination, recapitalization or other similar transaction effected without receipt of consideration that results in an increase in the number of outstanding shares of the Registrant’s Common Stock. |
(2) | Represents (i) 1,211,533 additional shares issuable under the Plan by reason of the automatic increase provisions of the Plan and (ii) 261,530 shares underlying certain equity awards previously issued under the Plan that have been forfeited or cancelled. |
(3) | Estimated pursuant to Rule 457(h) and Rule 457(c) under the Securities Act, solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Registrant’s Common Stock on September 28, 2021, as reported on the Nasdaq Global Select Market. |
EXPLANATORY NOTE
Intercept Pharmaceuticals, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 1,473,063 shares of its Common Stock, par value $0.001 per share (“Common Stock”), issuable to eligible persons under the Registrant’s 2012 Equity Incentive Plan, which shares of Common Stock are in addition to the shares of Common Stock registered on the Registrant’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 7, 2012 (File No. 333-184810), April 22, 2013 (File No. 333-188064), August 7, 2015 (File No. 333-206247), May 10, 2017 (File No. 333-217863), July 27, 2018 (File No. 333-226405), August 13, 2019 (File No. 333-233248), and August 17, 2020 (File No. 333-248083), the contents of all of which are incorporated by reference into this Registration Statement on Form S-8 pursuant to General Instruction E to Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
* Filed herewith.
† Unless otherwise specified, the File No. is 001-35668.
(1) Registration Statement on Form S-8 filed by the Registrant, Registration No. 333-184810.
(2) Registration Statement on Form S-1 filed by the Registrant, Registration No. 333-183706.
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 29, 2021.
INTERCEPT PHARMACEUTICALS, INC. | ||
By: | /s/ Jerome Durso | |
Name: | Jerome Durso | |
Title: | President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jerome Durso, Andrew Saik, Jared Freedberg, Rocco Venezia, and Mary J. Grendell, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing required or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned could do in person, and hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date | ||
/s/ Jerome Durso | President, Chief Executive Officer, and | September 29, 2021 | ||
Jerome Durso | Director (Principal Executive Officer) | |||
/s/ Andrew Saik | Chief Financial Officer | September 29, 2021 | ||
Andrew Saik | (Principal Financial Officer) | |||
/s/ Rocco Venezia | Chief Accounting Officer | September 29, 2021 | ||
Rocco Venezia | (Principal Accounting Officer) | |||
/s/ Paolo Fundarò | Chairman of the Board of Directors | September 29, 2021 | ||
Paolo Fundarò |
/s/ Srinivas Akkaraju, M.D., Ph.D. | Director | September 29, 2021 | ||
Srinivas Akkaraju, M.D., Ph.D. | ||||
/s/ Luca Benatti, Ph.D. | Director | September 29, 2021 | ||
Luca Benatti, Ph.D. | ||||
/s/ Daniel Bradbury | Director | September 29, 2021 | ||
Daniel Bradbury | ||||
/s/ Keith Gottesdiener, M.D. | Director | September 29, 2021 | ||
Keith Gottesdiener, M.D. | ||||
/s/ Nancy Miller-Rich | Director | September 29, 2021 | ||
Nancy Miller-Rich | ||||
/s/ Mark Pruzanski, M.D. | Director | September 29, 2021 | ||
Mark Pruzanski, M.D. | ||||
/s/ Dagmar Rosa-Bjorkeson | Director | September 29, 2021 | ||
Dagmar Rosa-Bjorkeson | ||||
/s/ Gino Santini | Director | September 29, 2021 | ||
Gino Santini | ||||
/s/ Glenn Sblendorio | Director | September 29, 2021 | ||
Glenn Sblendorio |
1 Year Intercept Pharmaceuticals Chart |
1 Month Intercept Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions